NASDAQ$CPRX
Catalyst Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
CPRX Q3 2024 — $2.1M revenue
Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. Catalyst Pharmaceuticals Inc reported Q3 2024 results. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $2.1M.
- Filed on Form 10-Q (accession 0000950170-24-122282).
Headline financials
Revenue & EPS history
Catalyst Pharmaceuticals · Revenue · Quarterly
$129M
Revenue by segment
Catalyst Pharmaceuticals · $153M total across 3 segments · Q4 2025
- FIRDAPSE$97.6M+18.3%64.0%
- AGAMREE$35.3M+67.5%23.1%
- FYCOMPA$19.6M-48.7%12.9%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-0.7%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+10.0%
Avg return
30 days after
38%
25 / 65 earnings
Positive
+29.1%
Q4 2016
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.0% | +0.1% | +0.6% | |
| Q4 2025 | +0.0% | -3.8% | -5.9% | |
| Q3 2025 | -1.9% | +8.0% | +10.1% | |
| Q2 2025 | -10.1% | -6.7% | -6.9% | |
| Q1 2025 | -3.0% | +0.8% | +10.3% | |
| Q4 2024 | +5.2% | +7.4% | +20.0% | |
| Q3 2024 | +5.9% | +6.8% | +0.3% | |
| Q2 2024 | +13.0% | +19.2% | +21.1% | |
| Q1 2024 | +3.4% | +7.1% | +3.2% | |
| Q4 2023 | +11.7% | +16.3% | +11.1% | |
| Q3 2023 | -4.1% | -1.7% | +10.1% | |
| Q2 2023 | +4.8% | +3.7% | -11.1% | |
| Q1 2023 | -18.7% | -24.5% | -33.2% | |
| Q4 2022 | +6.1% | +10.4% | +19.1% | |
| Q3 2022 | +0.7% | +2.7% | +6.8% | |
| Q2 2022 | +20.8% | +27.9% | +40.3% | |
| Q1 2022 | -0.5% | +5.7% | +1.7% | |
| Q4 2021 | -2.0% | +4.1% | +11.5% | |
| Q3 2021 | +2.7% | +18.0% | +4.3% | |
| Q2 2021 | +2.2% | +4.0% | -12.9% | |
| Q1 2021 | -1.9% | +14.1% | +17.2% | |
| Q4 2020 | +6.7% | +12.3% | +14.7% | |
| Q3 2020 | +7.9% | +7.9% | +12.4% | |
| Q2 2020 | -17.5% | -14.3% | -21.7% | |
| Q1 2020 | -5.7% | -6.4% | -6.6% | |
| Q4 2019 | -15.2% | -13.5% | +27.6% | |
| Q3 2019 | -9.6% | -11.6% | -13.9% | |
| Q2 2019 | +0.6% | -1.0% | +30.7% | |
| Q1 2019 | -0.3% | +20.7% | +16.9% | |
| Q4 2018 | +16.8% | +34.9% | +76.5% | |
| Q3 2018 | -4.9% | -14.5% | -26.2% | |
| Q2 2018 | +2.4% | +3.8% | +16.1% | |
| Q1 2018 | +0.7% | +21.2% | +23.4% | |
| Q4 2017 | -9.6% | -10.5% | -18.5% | |
| Q3 2017 | -4.2% | -6.1% | +28.2% | |
| Q2 2017 | -1.4% | +1.4% | -9.7% | |
| Q1 2017 | +2.2% | +12.2% | +32.8% | |
| Q4 2016 | +29.1% | +41.9% | +50.4% | |
| Q3 2016 | +4.0% | +12.9% | +16.8% | |
| Q2 2016 | -1.3% | -3.9% | +33.8% | |
| Q1 2016 | -6.3% | — | — | |
| Q4 2015 | -10.6% | — | — | |
| Q3 2015 | -5.3% | — | — | |
| Q2 2015 | -9.2% | — | — | |
| Q1 2015 | -1.5% | — | — | |
| Q4 2014 | +15.8% | — | — | |
| Q3 2014 | -6.3% | — | — | |
| Q2 2014 | -2.7% | — | — | |
| Q1 2014 | +2.8% | — | — | |
| Q4 2013 | +9.6% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | -6.3% | — | — | |
| Q1 2013 | -7.3% | — | — | |
| Q4 2012 | -5.1% | — | — | |
| Q3 2012 | -10.7% | — | — | |
| Q2 2012 | -7.9% | — | — | |
| Q1 2012 | -5.6% | — | — | |
| Q4 2011 | -6.1% | — | — | |
| Q3 2011 | +2.0% | — | — | |
| Q2 2011 | -6.6% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q4 2010 | -0.0% | — | — | |
| Q3 2010 | -0.5% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q1 2010 | -9.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro